You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202191 - 202200 of 207728 results
  1. Vaccine Strategies for Candidal Infections

    SBC: NOVADIGM THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Candida species are opportunistic fungal pathogens that have become among the most common causes of nosocomial infections in the United States and worldwide. Disseminated infections caused by Candida spp. have increased 15-fold in incidence in the last 15 years, and Candida is now the third most common cause of bloodstream infections. Even with modern antifunga ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  2. Vaccine therapy of congenital adrenal Hyperplasia

    SBC: L2 DIAGNOSTICS LLC            Topic: N/A

    N/A

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  3. VACCINE TO TREAT CHRONIC HEPATITIS B VIRUS INFECTION

    SBC: Cytel Corp.            Topic: N/A

    HEPATITIS B VIRUS (HBV) IS A HEPATOTROPIC VIRUS THAT IS A MAJOR PUBLIC HEALTH CONCERN WORLDWIDE. WHILE A RECOMBINANT SURFACE ANTIGEN VACCINE IS AVAILABLE, THERE IS NO EFFECTIVE TREATMENT FOR THE MILLIONS OF INDIVIDUALS WHO ARE CHRONICALLY INFECTED. THE OBJECTIVE IS TO DEVELOP PEPTIDE THERAPEUTICS THAT WILL GENERATE CYTOTOXIC T LYMPHOCYTES (CTL) IN VIVO AND MAY AMELEIORATE CHRONIC HBV INFECTIONS. T ...

    SBIR Phase II 1995 Department of Health and Human Services
  4. VACCINE TO TREAT CHRONIC HEPATITIS B VIRUS INFECTION

    SBC: Cytel Corp.            Topic: N/A

    N/A

    SBIR Phase I 1992 Department of Health and Human Services
  5. VACCINE VECTORS TO STIMULATE MUCOSAL IMMUNITY

    SBC: APPLIED BIOTECH CONCEPTS, INC.            Topic: N/A

    A MODEL WILL BE DEVELOPED TO CREATE EFFECTIVE VACCINE VECTORS THAT WILL ELICIT MUCOSAL (SECRETORY) IMMUNITY. RECOMBINANT VACCINIA VIRUS THAT EXPRESS ONE OR MORE ANTIGENSOF THE PSEUDORABIES VIRUS (PRV) WILL BE USED AS THE PROTOTYPE IN THE DESIGN OF THE FIRST-GENERATION VECTORS. THE LD50 (THE DOSE LETHAL FOR 50 PERCENT OF THE ANIMALS CHALLENGED) OF PRV IN MICE WILL FIRST BE DETERMINED AFTER INTRAPER ...

    SBIR Phase I 1989 Department of Health and Human Services
  6. VACCINIA IMMUNE GLOBULIN FROM CLONED TRANSGENIC CATTLE

    SBC: HEMATECH, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The SBIR proposal addresses a critical national need for therapies to treat complications from smallpox vaccination. Vaccination against smallpox is accompanied with numerous adverse reactions, some of which have high fatality rates. Ironically, it was the eradication of smallpox, which the WHO declared complete worldwide in 1979, and the cessation of routine i ...

    SBIR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  7. Vaccinia Proteome Affinity Reagents From Phage Display

    SBC: ImmPORT Therapeutics Inc dba Antigen Discovery Inc            Topic: N/A

    DESCRIPTION (provided by applicant): The need for nimble technology platforms to counter bioterrorism threats motivates the research proposed here. In this project, reagents with high affinity and specificity for vaccinia virus proteins will be select

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  8. Vacuum Arc Nano Thrusters for Nanosatellite Spacecraft Constellations

    SBC: ALAMEDA APPLIED SCIENCES CORPORATION            Topic: N/A

    "AASC, in collaboration with team member General Dynamics, Space Propulsion Systems, proposes to advance the Vacuum Arc Thruster (VAT) one step closer to flight qualification status. Phase I successfully demonstrated the low system mass and performancecharacteristics necessary to support "precision propulsion" requirements for constellation based, nano satellite missions. Phase II will benchmark t ...

    SBIR Phase II 2002 Department of DefenseAir Force
  9. Vacuum Arc Nano Thrusters for Nanosatellite Spacecraft Constellations

    SBC: ALAMEDA APPLIED SCIENCES CORPORATION            Topic: N/A

    Alameda Applied Sciences Corporation proposes to develop a new type of nano-thruster electric engine for highly parallel, distributed constellations of nano-satellites and other space propulsion applications. A key feature of the proposed Phase-I is theuse of an Inductive Energy Store (IES) driver to power the vacuum arc nano-thruster, which has a mass of 90% PPU efficiency from 1-10 W. The provin ...

    SBIR Phase I 2001 Department of DefenseAir Force
  10. Vacuum-assisted MIMIC for EMI grid application on spinel domes

    SBC: TECHNOLOGY ASSESSMENT AND TRANSFER, INC.            Topic: A08035

    Soft lithography is an inexpensive and fast method for applying micropatterned structures to both flat and nonplanar substrates. A vacuum-assisted Micromolding in Capillaries (MIMIC) technique will be developed to print a fine electromagnetic interference (EMI) grid on the inner surface of transparent spinel domes. A photocurable silver filled resin will infiltrate an EMI grid channel patterned ...

    SBIR Phase I 2008 Department of DefenseArmy
US Flag An Official Website of the United States Government